Antioxidant drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: What does evidence suggest?

Table 3 Outcome data of the randomized controlled trials included in this study

Ref.	Antioxidant group					Control group
	No. of patients (n)	No. of PEP cases (n)	PEP stratified according toseverity			No. of patients (n)	No. of PEP cases (n)	PEP stratified according to severity
			Mild	Moderate	Severe			Mild	Moderate	Severe
Wollschläger et al[34], 1999	20	2	NA	NA	NA	20	3	NA	NA	NA
Budzyńska et al[35], 2001	99	12	9	2	1	101	8	5	3	0
Lavy et al[36], 2004	141	14	10	4	0	180	17	9	4	4
Katsinelos et al[37], 2005	124	15	8	7	0	125	12	7	5	0
Katsinelos et al[38], 2005	125	4	4	0	0	118	21	8	11	2
Mosler et al[39], 2005	355	46	28	16	2	346	42	24	16	2
Milewski et al[40], 2006	55	4	NA	NA	NA	51	6	NA	NA	NA
Kapetanos et al[41], 2007	158	9	6	1	2	162	5	4	0	1
Romagnuolo et al[42], 2008	293	16	8	6	2	293	12	4	6	2
Martinez-Torres et al[43], 2009	85	2	2	0	0	85	8	8	0	0
Abbasinazari et al[44], 2011	29	3	2	1	0	45	5	3	2	0
Alavi Nejad et al[45], 2013	50	5	NA	NA	NA	50	14	NA	NA	NA
Total	1534	132				1576	153

ERCP: Endoscopic retrograde cholangiopancreatography; PEP: Post-ERCP pancreatitis; NA: Not available.